ReoPro, (abciximab) dosing, indications, interactions, adverse effects, and more

Sections

Sections abciximab
Dosing & Uses
Interactions
Adverse Effects
Warnings
Pregnancy
Pharmacology
Administration
Images
Patient Handout
Formulary

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injectable solution

2mg/mL

Adjunct to PCI

Prevention of cardiac ischemic complications in patients undergoing PCI

0.25 mg/kg IV bolus over at least 1 min, 10-60 min before start of PCI, THEN

0.125 mcg/kg/min IV continuous infusion for 12 hr; not to exceed infusion rate of 10 mcg/min

Unstable Angina

Indicated for prevention of cardiac complications in patients with unstable angina with PCI planned within 24 hr

0.25 mg/kg IV bolus over at least 1 minute, THEN

0.125 mcg/kg/min IV continiuous infusion for 18-24 hr concluding 1 hour post-PCI; not to exceed 10 mcg/min

Stop continuous infusion of abciximab in patients with failed PCIs

Other Indications & Uses

Adjunctive therapy during thrombolysis (off-label)

Safety and efficacy not established

Interaction Checker

Enter a drug name and abciximab

No Results

No Interactions Found

Interactions Found

Contraindicated

Serious - Use Alternative

Significant - Monitor Closely

Minor

All Interactions Sort By:

>10%

Bleeding, minor (70-82%)

Bleeding, major (17-21%)

Hypotension (14-21%)

Back pain (17.6%)

Nausea (13.6%)

Chest pain (11.4%)

Vomiting (7-11%)

1-10%

Headache (6%)

Thrombocytopenia (2-6%)

Bradycardia (5%)

Injection site pain (3.6%)

Extremity pain (3.5%)

Abdominal pain (3%)

UTI (2%)

Dizziness (1.8%)

Peripheral edema (1.6%)

Anemia (1.2%)

Diarrhea (1%)

Hypoesthesia (1%)

Contraindications

Hypersensitivity

Active major bleeding, thrombocytopenia, history of CVA (within 2 years)

Peptic ulcer disease

Recent surgery of trauma, intracranial neoplasm, uncontrolled HTN, vasculitis

Oral anticoagulant use within 7 days increases bleeding risk

Cautions

Intended for use with aspirin and heparin, and has only been studied in that setting

Increased bleeding risk when used with thrombolytic agents

Thrombocytopenia

Monitor platelet counts prior to, during, and after treatment
Acute decreases in platelet count should be differentiated between true thrombocytopenia and pseudothrombocytopenia
If true thrombocytopenia is verified, therapy should be immediately discontinued and the condition appropriately monitored and treated

Pregnancy & Lactation

Pregnancy Category: C

Lactation: not known if excreted in breast milk; use caution

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Mechanism of Action

Chimeric monoclonal antibody; prevents binding of fibrinogen, vWF to glycoprotein IIb/IIIa receptor sites on platelets

Pharmacokinetics

Half-life: 30 min

Onset: 10 min (<20% of baseline)

Duration: 72 hr

Metabolism: Through proteolytic cleavage

Platelet binding: Remains bound for 15 days

Peak time: ~30 min (platelet inhibition)

IV Compatibilities

Solution: D5W, NS

Y-site: adenosine, atropine, bivalirudin, diphenhydramine, fentanyl, metoprolol, midazolam

IV Preparation

Do not add any other drugs in same IV line

Bolus injection: withdraw through 0.22 micron filter

Infusion: withdraw 4.5 mL (9 mg) through filter into syringe; inject into 250 mL of NS or D5W; final concentration 35 mcg/mL

Do not shake vial

IV Administration

Bolus over at least 1 min

See adult dosing for infusion rate

Images

Patient Handout

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Create Your List of Plans

Adding plans allows you to:

View the formulary and any restrictions for each plan.
Manage and view all your plans together – even plans in different states.
Compare formulary status to other drugs in the same class.
Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

View explanations for tiers and restrictions

Tier	Description
1	This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2	This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC	NOT COVERED – Drugs that are not covered by the plan.

Code	Definition
PA	Prior Authorization Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL	Quantity Limits Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST	Step Therapy Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR	Other Restrictions Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.

Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.

[CLOSE WINDOW]

Sections abciximab
Dosing & Uses
Interactions
Adverse Effects
Warnings
Pregnancy
Pharmacology
Administration
Images
Patient Handout
Formulary

abciximab (Rx)